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Summary 
In the transmembrane domain and cytoplasmic domain of human CD44 protein there are two 
cysteine residues. These two cysteines are conserved in all known mammalian CD44 proteins. 
The functions of these cysteine residues are not known. Site-specific  mutagenesis was used to cre- 
ate CD44  mutant proteins lacking either one or both of these cysteine residues. Wild-type 
CD44 and mutant CD44 genes were transfected into CD44- Jurkat cells to establish stable trans- 
fectants. These transfectants  were used to study whether these two cysteine residues are important 
in the binding of CD44(H) to fluorescein-conjugated hyaluronic acid (F-HA). Jurkat transfec- 
tant bearing wild-type CD44 did not bind F-HA, unless they were stimulated in vitro with im- 
mobilized anti-CD3 monoclonal antibody. Anti-CD3 antibody also stimulated the binding of 
F-HA in Jurkat CD44.C295A transfectant in which the cytoplasmic cysteine residue has been re- 
placed with alanine. In contrast, anti-CD3 antibody failed to stimulate the binding of F-HA in 
Jurkat transfectant (CD44.C286A), in which the transmembrane domain cysteine 286 has been re- 
placed with an alanine, and in Jurkat transfectant CD44.2C2A, in which both of the cysteine 
residues have been altered. Binding can also be induced with a monoclonal anti-CD44 antibody 
(F-44-10-2) in Jurkat wild-type CD44 and Jurkat CD44.C295A transfectants but not in CD44. 
C286A transfectant. These results provide evidence that the transmembrane domain of CD44, 
more specifically the cysteine residue in the transmembrane domain, is important for both acti- 
vation-induced and anti-CD44 antibody-induced binding of soluble HA. 
C 
D44 is a glycoprotein expressed on lymphocytes, mono- 
cytes, and many other cell types  (1-4). There are at 
least 20 exons in the CD44 gene (5-8). Potentially, a large 
number of CD44 isoforms can be generated by differential 
splicing of the mlKNA. The mature hematopoietic form is a 
80-90-kD transmembrane protein (CD44H), and represents 
the basic unit of the CD44 proteins. The other CD44 iso- 
forms are created by addition of new exons into the extra- 
cellular domain of CD44H (5-8). The hematopoietic form 
of CD44 is the major CD44 protein present on normal hu- 
man lymphocytes and monocytes. 
One of the ligands for CD44 is hyaluronic acid (HA) (9- 
11). HA is a proteoglycan present in extracellular matrix and 
in the circulation (12,  13). There is a single tandem repeat 
loop on the extracellular domain of CD44H, which may be 
important in interactions between CD44 and HA. This re- 
gion is conserved in all CD44 isoforms (1-4). Two regions 
in the human CD44 molecules have been identified to be 
important in hyaluronic acid binding. One of the regions is 
located near the amino terminus. The other site is located near 
1Abbreviations used in this paper: F-HA, fluorescein-conjugated  hyaluronic 
acid; HA, hyaluronic  acid. 
the membrane proximal region but lies outside the link pro- 
tein homologous domain (14). Using blocking monoclonal 
antibodies, an additional region in the CD44 molecule has 
been proposed to be important for binding of HA (15). 
Binding of soluble HA to cell surface CD44 can be dem- 
onstrated with some, but not all CD44-bearing cells (3, 16). 
Normal lymphocytes or monocytes do not bind HA, despite 
the expression of high levels of CD44 (16).  Stimulation of 
normal murine splenic B  cells with anti-IgD  and dextran 
generated a population of  B cells which expressed the high- 
est levels of cell surface CD44. However, these B  cells did 
not bind fluorescein-conjugated hyaluronic acid (F-HA). In 
contrast, splenic B  cells stimulated with IL-5 expressed ei- 
ther equivalent or lower levels of CD44 but bound signifi- 
cant levels of F-HA (17). Therefore, simple upregulation of 
CD44 expression is insufficient to ensure binding ofF-HA, 
and  level  of CD44  expression does  not  always  correlate 
with binding of F-HA. Binding of low levels of HA can be 
induced with some anti-CD44 mAbs, indicating that con- 
formational changes  as  a  result  of cross-linking of CD44 
may be essential for binding of HA (18,  19). 
Posttranslational modifications, especially N-linked glyco- 
sylation of CD44 influence binding of HA (16,  17, 20, 21). 
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tions between CD44 and HA (22). Furthermore, the isoforms 
of CD44 expressed also influence binding of HA (3,  16). 
The  cytoplasmic domain  of CD44 interacts  with  cyto- 
skeletal  proteins,  more  specifically  with  ankyrin  (23-26). 
Ankyrin is important in membrane cytoskeletal interactions 
(27).  Whether  interactions  between  the  cytoplasmic  do- 
main  of CD44  and  cytoskeletal proteins  are  important  in 
binding of HA is controversial. Some studies suggested that 
the  cytoplasmic  domain  was  essential  for binding  (28--30). 
Other studies suggested that interactions between the CD44 
cytoplasmic domain  and cytoskeletal protein  were not re- 
quired for binding (14, 31). A  chimeric, genetic engineered 
soluble human  CD44 protein lacking the  authentic  CD44 
cytoplasmic  domain  binds  HA,  suggesting  that  an  intact 
CD44 cytoplasmic domain was not essential  for binding (14). 
The reasons for these discrepancies are not known. Whether 
CD44 interacts  with  cytoplasmic skeletal  proteins may de- 
pend on the  nature  of the  cell type.  The cytoplasmic do- 
main  of CD44  is  subject  to phosphorylation by a  serine/ 
threonine protein kinase and was reported to be essential for 
binding  of HA  (32).  CD44  has  GTPase  activity.  Binding 
and hydrolysis of GTP by CD44 may regulate the interac- 
tions between CD44 and cytoskeletal proteins (33).  Under- 
hill and Toole proposed that clustering of CD44 on the cell 
surface may be important for binding of HA (34, 35). Clus- 
ters of CD44 are more likely to make multiple interactions 
with  a  single  molecule  of HA  than  if they  are  dispersed 
over the cell surface. Large molecules of HA bind to the cell 
surface with a higher affinity than smaller molecules  (34).  In 
addition, when membranes are solubilized with a detergent, 
the binding affinity of CD44 is drastically decreased (35). 
All human CD44 isoforms have identical transmembrane 
and cytoplasmic domains (1-4). The putative transmembrane 
domain  of CD44H  (amino  acids  270  to  289)  and  the  18 
amino acid immediately after the transmembrane domain are 
identical in mouse, baboon, horse, rat, mouse, and human. 
In the hamster, there is one conserved change from isoleucine 
to valine in position 272  (28).  This high degree of conser- 
vation may signify the importance of this region in the func- 
tions of CD44 molecules. Within this highly conserved region 
of  human CD44H, there are two cysteine residues. Cys 286 
is located in the transmembrane domain and Cys 295 is lo- 
cated in the cytoplasmic domain. Whether these two cysteines 
are important in the functions of CD44 is not known. 
Cysteine residues in the transmembrane domain and in the 
cytoplasmic domain of some transmembrane cell surface pro- 
teins are covalently modified with a long chain saturated fatty 
acid, a process known as protein palmitoylation (36--39).  The 
functions of protein palmitoylation are not clear. Palmitoy- 
lation of proteins may facilitate protein-protein interactions 
and/or  protein-lipid  interactions.  No  uniform  consensus 
function  has  been  established  for  protein  palmitoylation. 
CD44  protein  in  murine  thymoma BW5147  (40)  and  in 
normal human peripheral blood lymphocytes (41) is modi- 
fied with palmitate.  There is a correlation between induc- 
tion of CD44 palmitoylation and inhibition of CD3-medi- 
ated signaling in human peripheral blood lymphocytes (41). 
Therefore, palmitoylation of CD44 may play a role in sig- 
nal transduction. 
We used site-specific mutagenesis to replace the two cys- 
teine residues in the transmembrane domain and in the cy- 
toplasmic  domain  of human  CD44,  either individually  or 
together,  with  alanine.  These  constructs  were  then  trans- 
fected into a CD44 negative human T  cell leukemia cell line, 
Jurkat. Stable transfectants were established and used to study 
interactions between CD44 and HA. Our results suggest that 
the transmembrane domain of CD44 is important in activa- 
tion induced binding of HA. More specifically, cysteine 286 
within the transmembrane domain, but not cysteine 295 in 
the cytoplasmic domain is critical for binding of HA. 
Materials  and Methods 
Cell Line and Chemicals.  Jurkat is a human leukemia cell line ori- 
ginally obtained from American Type Culture Collecfon (ATCC, 
lq,  ockville,  MD). All tissue culture media,  fetal calf serum,  antibi- 
otics,  restriction  enzymes,  and hygromycin were obtained from 
GIBCO BILL (Gaithersburg,  MD). Anti-CD44 monoclonal anti- 
body F10-44-2 was obtained from Serotec,  Harlan Bioproducts 
(Indianapolis,  IN). 
Site Specific Mutagenesis and Transfection.  There are the only two 
Cys residues  in  the  entire  transmembrane  and  cytoplasmic  do- 
main of CD44.  The Unique Selection  Elimination  method was 
used  to generate CD44 mutant constructs  (42). Codons for Cys 
286 and Cys 295 were either changed to alanine  individually  or 
in combination. All mutants have been verified by sequencing us- 
ing  Sequenase  version  2.0  DNA  sequencing  Kit  from  United 
States Biochemical Co. (Cleveland,  OH). 
Mutated and wild-type CD44 constructs were subcloned into 
pCEP-4 (kindly provided by Dr. Robert Peter'son of the Institute 
of  Pathology, CWRU) which contains the CMV promoter and the 
hygromycin resistance  gene  (43).  The construct was transfected 
into Jurkat by electroporation. Briefly, ten million  cells were sus- 
pended in 0.4 ml HeBS buffer. Then 20 Ixg of DNA and 200 pig 
of carrier DNA were added and pulsed at setting:  260V,  960 uF. 
The cells were then cultured in ILPMI, 10% FCS for 2 d before 
selection.  The transfectants  were selected  with  1 mg/ml hygro- 
mycin. The expression  of CD44 was verified by immunofluores- 
cent staining with anti-CD44 mAbs and analyzed by FACS. 
Biotinylation,  Immunoprecipitation  and  Western Blotting  of CD44 
Proteins.  Cells were surface labeled  with a biotinylation proce- 
dure as described  (44). Briefly, cells (107/ml) were incubated with 
sulfosuccinomidobiotin (Pierce Co,, Rockford, IL) (0.1 mg/ml) in 
labeling buffer (150 DxM NaC1, 0.1 M Hepes, pH 8) for 30 rain at 
room temperature.  Cells were then washed with ILPMI medium 
supplemented with 3% FCS and lysed with l% Triton X-100 in 
10 mM Tris, pH 7.5,  150 rnM NaC1, 3 mM EDTA, 50 mM io- 
doacetamide, 0.1% NaN  3, 1 mM PMSF, 10 btg/ml of  soybean tryp- 
sin inhibitor,  1 txg/ml leupetin, and I U/ml of aprotinin for 1 h 
at 4~  The detergent solubilized  materials  were recovered after 
centrifugation and precleared  with an irrelevant  antibody Sepha- 
rose  4B beads,  followed by immunoprecipitation  with  an  anti- 
CD44 mAb A3.  After extensive  washing,  proteins  were  eluted 
from beads  by boiling in reducing SDS  sample  buffer and ana- 
lyzed by SDS-PAGE with  a 7.5%  gel.  Separated  proteins were 
then transferred to a nitrocellulose  membrane. The membrane was 
blocked with 0.5% gelatin in PBS plus 0.05% Tween 20 and 0.05% 
thimerosal  for 1 h at room temperature.  After incubation mem- 
branes were incubated with 1/1,000 or 1/500 diluted streptavidin- 
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Tween 20. The protein bands were detected using the enhanced 
chemiluminescence system (Amersham Corp., Arlington Heights, 
IL). Prestained  molecular mass markers were used as standards. 
In Vitro Induction of Binding with anti-CD3 mAb.  Jurkat cells and 
Jurkat cells bearing different  CD44 mutant proteins (5 X  10S/ml) 
were cultured in RPMI medium (1KPMI supplemented with 10% 
FCS and 1% antibiotics).  For activation of  binding with anti-CD3 
mAb, cells were cultured in 24- or 96-weU tissue culture plates pre- 
coated with different concentrations of an anti-CD3 mAb (12F6). 
Cultures  were  placed in  a  5%  humidified  CO2 incubator for 
16-18 h. After culture,  cells were harvested  and washed exten- 
sively before staining with mAb or F-HA. 
Immunofluorescence Staining and Hyaluronate Binding Assay.  Cul- 
tured cells were harvested and washed with washing medium (PBS 
supplemented with  5% New born calf serum,  0.1%  NaN  3, pH 
7.4).  Single cell suspension  (1  X  106/ml) was incubated with af- 
finity-purified mAbs on ice for 45 min or an isotype control anti- 
body. Cells were washed three times with washing medium and 
25 p,1 FITC-conjugated goat anti-mouse IgG antibody was added 
for 45 min on ice. Finally, samples were washed and fixed with 1% 
paraformaldehyde.  FITC-HA was  prepared  by a  modified con- 
jugation protocol described earlier (45). Briefly, hyaluronic acid so- 
dium salt (H-4015;  Siena Chemical Co., St. Louis, MO) was dis- 
solved in 20% DMSO and coupled to fluorescein  amine by using 
isocyanide. 25 p,1 of FITC-HA (10 p,g/ml) was added into cell sam- 
ples and incubated on ice for 45  rain.  All samples were washed 
and fixed as described.  Cells were analyzed in a FACScan  |  (Bec- 
ton Dickinson, San Jose, CA). At least 5,000 cells were analyzed 
per sample in all experiments.  All experiments were done at least 
three times.  In all experiments two controls are always included. 
One control is blocking of  binding ofF-HA with uncojugated HA, 
and the other control is blocking of binding with a anti-CD44 
mAb A.3. 
Results 
Generation  of Stable Jurkat  Transfectants  Expressing  Either 
Wild-type  Human  CD44H Protein or Mutant CD44H Proteins. 
In the  transmembrane  domain  of human  CD44,  there  is 
one cysteine residue in position 286 (Cys286). Another cys- 
teine residue is in the cytoplasmic domain, in position 295 
(Cys295). These two cysteines are the only two cysteines in 
the transmembrane and cytoplasmic domain of CD44. We 
replaced each of the cysteines residue individually with ala- 
nine  (CD44.C286A  and  CD44.C295A)  or replaced  both 
of the cysteine residues with alanine (CD44.2C2A) by site- 
specific mutagenesis (Fig. 1 A). Constructs were then trans- 
fected individually into a CD44- human leukemia cell hne, 
Jurkat.  Stable  transfectants were selected and characterized 
by immunofluorescent  staining  with  anti-CD44  mAbs  as 
described in Materials and Methods. 
All mutant CD44 proteins were present on the cell sur- 
face ofJurkat  transfectants  (Fig.  1 B). The levels of CD44 
protein  expression  were  comparable  in  all  three  mutants. 
Therefore,  the  cysteine  residues  are  not  essential  for  the 
expression of CD44 on the cell surface, and palmitoylation 
of the CD44 molecule is not essential for membrane local- 
ization of CD44 protein. Western blotting was used to ver- 
ify the molecular mass of wild-type CD44 and mutant CD44 
proteins on Jurkat transfectants. Identical numbers of  Jurkat 
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wild-type  CD44  transfectant  and  CD44.C286A,  CD44. 
C295A, and CD44.2C2A transfectants were surface biotiny- 
lated and immunoprecipitated with anti-CD44 mAb. Immu- 
noprecipitated proteins were transferred to a nitrocellulose 
membrane and blotted with strepavidin-conjugated horse- 
radish  peroxidase  as  described  in  Materials  and  Methods. 
Similar  to the  wild-type  CD44 protein,  the  three  mutant 
CD44  proteins  also  had  molecular  masses  of 75-85  kD. 
(Fig.  2).  Therefore,  alteration  of the  cysteine residues  did 
not significantly change the overall posttranslational  modi- 
fications  of the  CD44  proteins.  No  high  molecular  mass 
CD44 protein was detected in any of the transfectants indi- 
cating that  CD44 was not modified with glycosaminogly- 
cans in these cells. 
Cysteine 286 in the Transmembrane Domain but not Cysteine 
295 in the Cytoplasmic Domain Is Important  for Binding ofF-HA. 
Jurkat CD44 transfectants do not bind F-HA, however, bind- 
ing of high levels of F-HA can be induced by immobilized 
anti-CD3 mAb. We used the three mutant CD44 transfec- 
tants, CD44.C286A, CD44.C295A, and CD44.2C2A to in- 
vestigate whether the cysteine residues in position 286 and 
295  are essential for anti-CD3-induced binding of F-HA. 
First,  we  estabhshed  that  all  three  mutant  CD44  transfec- 
tants expressed similar levels of CD3 proteins on their sur- 
face,  as  compared to  the  wild-type  CD44  transfectant  by 
immunofluorescent  staining  with  a  anti-CD3  mAb.  (Re- 
sults  not shown.)  Second,  we verified that  CD3  signaling 
pathways in these  three  transfectants  were functional.  Im- 
mobilized anti-CD3 mAbs stimulated the production oflL-2 
in all three transfectants (Liu, D., and M.S. Sy, manuscript in 
preparation).  Experiments  were then carried out to deter- 
mine whether immobilized anti-CD3 mAb can induce bind- 
ing ofF-HA in CD44.C286A, CD44.C295A or CD44.2C2A 
transfectants.  The parental CD44 negative Jurkat was used 
as a negative control, and the Jurkat wild-type CD44 trans- 
fectant was used as a positive control. 
Parental CD44-Jurkat did not bind F-HA in all doses of 
anti-CD3 mAb tested.  In contrast, anti-CD3 mAb induced 
high levels of binding in wild-type CD44 transfectants and 
in CD44.C295A transfectants in a dose-dependent manner 
(Fig. 3, A  and B).  In these two cell hnes, significant levels 
of binding can be induced with as httle as 1 p~g/ml of anti- 
CD3  mAb.  However,  the  levels  of binding  observed  in 
CD44.C286A and  CD44.2C2A transfectants  were signifi- 
candy reduced  in  all  doses  of anti-CD3  mAb tested.  The 
difference  was most dramatic  when  a  lower dose  of anti- 
CD3 mAb was used.  1 p~g/ml of anti-CD3 was unable to 
stimulate binding of HA in CD44.C286A and CD44.2C2A 
transfectants.  The inability of CD44.C286A to bind F-HA 
after stimulation with anti-CD3 was confirmed with another 
independently isolated CD44.C286A transfectant. Binding of 
F-HA to Jurkat CD44 transfectant is specific for CD44 and 
hyaluronic acid because binding can be completely inhib- 
ited  with  unconjugated hyaluronic  acid  or with  a  mono- 
clonal anti-CD44 antibody A.3. (16 and results not shown). 
Activation of Jurkat  CD44 transfectants  with  anti-CD3 
upregulated  the  expression  of CD44 proteins.  The failure 
of anti-CD3  to induce binding in CD44.C286A transfec- A 
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Figure  1.  (A)  The amino acid sequences of 
the transmembrane domain of wild type human 
CD44 and mutant CD44H proteins. (B) Expres- 
sion of wild-type CD44  protein and  mutant 
CD44 proteins onJurkat transfectants. All trans- 
fectants were stained first with an  ann-CD44 
n'LAb GKW.A3 and then followed with a fluo- 
rescein-conjugated rabbit anti-mouse lg second 
step antibody as described (15). All samples were 
fixed and analyzed  in a FACScan  |  At least 5,000 
cells were analyzed in each sample. Clear areas 
were negative controls, which were cells stained 
with an irrelevant, isotype matched monoclonal 
antibody. F.l. = fluorescein intensity. 
tant was not due to the lack of enhancement of CD44 ex- 
pression  on CD44.C286A transfectant.  Culture  of CD44. 
C286A and CD44.C295A with  anti-CD3  mAb enhanced 
the expression of CD44 proteins to a similar degree (Fig. 4). 
Nevertheless, only CD44.C295A bound high levels ofF-HA. 
Therefore, upregulation of CD44 expression by itself is in- 
sufficient  to  warrant  binding  of HA.  Furthermore,  anti- 
CD3 did not induce detectable cell surface CD44 on CD44 
negative parental Jurkat T  cells  or Jurkat T  cells  transfected 
with a hygromycin-resistant gene without the CD44 sequence 
(Jurkat/pCEP)  (Fig.  4). Therefore, anti-CD3 did not induce 
the expression of endogenous CD44 gene in Jurkat cells. 
Induction  of Binding  with  Monoclonal Anti-CD44  Anti- 
body.  Binding  of F-HA  can  be  induced  by  some  anti- 
CD44  mAbs  (17,  18).  In  contrast  to  activation-induced 
binding,  anti-CD44 antibody-induced binding occurs rap- 
idly and does not require in vitro culture. Induction of bind- 
ing by anti-CD44 mAb may simply involve aggregation of 
CD44 molecules on the  cell surface by the bound mono- 
clonal  antibody.  We  investigated  whether  one  of these 
anti-CD44 antibodies,  F10-44-2 induces binding of F-HA 
in Jurkat wild-type CD44 transfectant and in mutant CD44 
transfectants. First, we established  that Jurkat wild-type CD44, 
CD44.C286A and CD44.C295A transfectants expressed com- 
parable levels of the epitope bound by F10-44-2.  (Fig. 5 A). 
Incubation  of Jurkat  wild-type  CD44  transfectant  and 
CD44.C295A transfectants  with  FI0-44-2 resulted  in sig- 
nificant levels of binding (Fig. 5 B).  Surprisingly, F10-44-2 
was  unable  to  induce  any  detectable  binding  in  CD44. 
C286A transfectant (Fig. 5 B). No binding was detected even 
when higher concentrations of F10-44-2 were added.  (re- 
sults not shown). These results provided evidence that similar 
to anti-CD3-induced binding, Cys286 in the transmembrane 
domain is also important m  anti-CD44 mAb-induced bind- 
ing. Therefore, induction of binding by anti-CD44 mAb is 
not a passive aggregation event but a cellular response,  re- 
quiting  the  presence  of the  Cys 286  residue  in  the  trans- 
membrane domain. 
Discussion 
Jurkat CD44 transfectants do not constitutively bind F-HA. 
However,  binding  can  be  induced  by immobilized  anti- 
CD3 mAb, PMA or a monoclonal anti-CD44 antibody (18). 
In this manuscript we provide evidence that a cysteine resi- 
due located in the transmembrane domain of CD44 is essen- 
tial  for both  anti-CD3-  and  anti-CD44-induced  binding 
of F-HA. The reasons why activation is required for bind- 
ing  of F-HA in  some  cells  are  not  clear.  Activation with 
anti-CD3 enhanced the expression of CD44 protein. How- 
ever,  enhancement of CD44 expression by itself is insuffi- 
cient to allow binding.  Treatment  ofJurkat  CD44.C286A 
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type CD44 protein and mutant CD44 
proteins  on  Jurkat  Transfectants. 
Transfectants  were  first biotinylated 
and  immunoprecipitated  with  anti- 
CD44 mAb. Immunoprecipitated pro- 
teins were then transferred to nitrocel- 
lulose  membrane.  Western  blotrings 
were carried out as described in Mate- 
rials and Methods. Lane A was from 
the wild-type CD44 transfectant; lane 
B was from the CD44.C286A transfec- 
tant; lane C was from the CD44.C295A 
transfectant;  lane  D  was  from the 
CD44.2C2A  transfectant.  Molecular 
masses are marked on the left. 
mutant transfectants with anti-CD3 mAb also increased the 
expression  of CD44,  to  a  level  comparable  to  wild-type 
CD44-bearing  cells.  Nevertheless,  CD44.C286A  mutants 
bound less F-HA than wild-type CD44 Jurkat transfectants 
orJurkat CD44.C295A transfectants. 
Since  all  the  CD44  constructs  used  in  our  studies  are 
placed under the control of CMV promoter, the molecular 
mechanisms  responsible for the upregulation of CD44  ex- 
pression in these Jurkat transfectants are not known.  In ad- 
dition to anti-CD3 treatment, PMA treatment upregulated 
the expression of CD44  on Jurkat transfectants (18).  Since 
activation with anti-CD3 mAb did not induce the expres- 
sion of the endogenous CD44 gene, therefore, the binding 
studies described here can be attributed solely to the trans- 
fected, and expressed CD 44 gene products. 
When stimulated with a sub-optimal anti-CD3 concen- 
tration  (1  ~g/ml),  CD44.C286A  transfectants were  com- 
pletely inactive. Low levels of binding of F-HA can be in- 
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duced in CD44.C286A and CD44.2C2A transfectants with 
higher  doses  of anti-CD3  mAb.  Some  other  mechanisms 
could compensate for the  lack of Cys 286  when  the  ceils 
were  stimulated with high doses of anti-CD3.  The  failure 
of anti-CD3  mAb  to  induce  binding  on  CD44.C286A 
transfectants was not because these transfectants did not re- 
spond to anti-CD3 mAb. Jurkat CD44.C286A transfectant 
and Jurkat wild-type CD44 transfectants expressed compa- 
rable levels of CD3  complex. Anti-CD3 mAb induced the 
production of IL-2 by CD44.C286A  transfectants, indicat- 
ing that all the necessary CD3 signal transduction compo- 
nents  are  present  in  CD44.C286A  transfectants.  CD44. 
C286A  and  wild-type CD44  transfectants  reacted equally 
to four different anti-CD44 mAb (results not shown). There- 
fore,  simply replacing the  Cys286  residue  did not  signifi- 
cantly alter the overall+ conformation of the protein. 
Glycosylation of CD44  is important  in  the  binding  of 
F-HA. Treatment  of cells with tunicamycin enhanced the 
binding of F-HA and also significantly reduced the molec- 
ular mass of CD44 protein.  (16,  20,  21). Western blotting 
of CD44 proteins from wild-type CD44 and CD44.C286A 
mutant transfectants failed to reveal any obvious change in 
the molecular size of these two proteins. Furthermore, im- 
munoprecipitation followed by two-dimensional gel elec- 
trophoresis also failed to detect any significant changes in the 
pI of CD44.C286A protein (results not shown). Therefore, 
posttranslational events like N-linked and O-hnked glyco- 
sylation were  not  grossly disrupted in  CD44.C286A  mu- 
tants.  A  more  extensive biochemical study  is required  to 
rule out the possibility that minor changes in the glycosyla- 
tion of CD44  may occur in CD44.C286A  protein. Alter- 
ation of the cysteine residue in the transmembrane domain 
may also influence the stability ofceU surface CD44, which 
CD44.C286A 
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CD44.C295A 
'"i'+t .....  i"62 .....  i'+3 ..... 
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Figure  3.  Anti-CD3  mAb 
does not stimulate high levels of 
binding  in  CD44.C286A  trans- 
fectant. (A) Parental CD44- Jur- 
kat,  Jurkat  wild-type  CD44 
transfectant  and  Jurkat  CD44 
mutant  transfectants were  cul- 
tured  in vitro  in 24-well  tissue 
culture plates precoated overnight 
with  different concentrations of 
purified  monoclonal  anti-CD3 
antibody  (12F6) for  18 h.  After 
culture,  ceils were  harvested, 
washed  extensively, and  then 
stained with F-HA as described 
(15). All samples were fixed and 
analyzed in a FACScan  |  At least 
5,000 cells  were analyzed in each 
sample. (/3) A representative his- 
togram of binding  of F-HA on 
Jurkat  CD44.C286A  and Jurkat 
CD44.C295A  transfectants after 
in vitro stimulation with 10 b~g/ 
ml  of  immobilized  anti-CD3 
mAb.  Shaded areas were  nega- 
tive  controls,  which  were  cells 
first  incubated  with  unconju- 
gated HA and then stained with 
F-HA. 
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Figure 4.  Anti-CD3 stimulation upregulates the expression of CD44 
on Jurkat CD44, CD44.C286A, and CD44.C295A transfectants  but not 
on Jurkat or Jurkat/pCEP. Jurkat CD44 transfectants or CD44 negative 
parental Jurkat or Jurkat T cells transfected with a hygromycin-resistant 
gene (CD44/pCEP) were cultured in vitro in 24-well tissue culture plates 
precoated overnight with different concentrations  of purified monoclona! 
anti-CD3 andbody (12F6) for 18 h. After culture, cells were harvested, 
washed  extensively, and  then  stained with  an  anti-CD44  rnAb 
(GKW.A3) as described (15). All samples were fixed and analyzed in a 
FACScan  |  At least 5,000 cells were analyzed  in each sample. 
may be critical for binding ofF-HA. We ruled out this pos- 
sibility by carrying metabolic labeling and pulse chase experi- 
ments. The half-life of wild-type CD44 protein on Jurkat 
CD44  transfectant is  ~18-24  h.  Replacing the  Cys  286 
residue did not the alter the half life of CD44.C286A mol- 
ecule on the cell surface (results not shown). 
CD44 protein is normally present on the cell surface as a 
80-95 kD monomer. The { chain ofmurine CD3 complex 
exists as disulfide bonded homodimer on the cell surface. Arti- 
ficial replacement of the transmembrane domain of murine 
CD44 with the transmembrane domain of { chain of CD3 
resulted in the dimerizarion of CD44 proteins, and binding 
of HA (29). Therefore, it is possible that activation by anti- 
CD3 mAb may induce homo-dimerization CD44 or het- 
ero-dimerization of CD44 with another protein via Cys286. 
Dimerization of CD44 via Cys286 will then permit bind- 
ing of HA, a situation similar to the artificial replacement of 
the  transmembrane domain of CD44 with the  transmem- 
brane domain of the ~ chain ofCD3. Dimerization of CD44 
can not occur in CD44.C286A transfectants, therefore, the 
cell remains unable to bind HA. We have obtained evidence 
that cysteine 286 in the transmembrane domain of CD44 is 
involved in the activation induced dimerization of CD44, 
and dimerization of CD44 is one of the critical events essential 
for binding of F-HA. (Liu, D., manuscript in preparation). 
Our observation that cysteine 286 in the transmembrane 
domain of CD44 is essential for dimerization of CD44 raise 
an interesting question concerning the role of CD44 pal- 
mitoylation in the biology of CD44 molecule, and the rela- 
tionship between CD44  palmitoylation and dimerization. 
Cysteine 286 and cysteine 295  are the  only two potential 
site for palmitoylation in CD44.  Palmitoylation of isolated 
murine CD44 protein from the thymoma, BW5147, has been 
reported to be important for binding of CD44 to  ankyrin 
in vitro (26).  Interactions between CD44 and ankyrin has 
also been reported to be essential for binding ofF-HA (31). 
However, since Jurkat CD44.C295A transfectant can bind 
F-HA when stimulated with anti-CD3, therefore,  palmi- 
toylation of CD44 at cysteine 295 is not essential for bind- 
ing of F-HA. It should be noted that BW5147 can consti- 
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Figure  5.  F10-44-2 can  not 
induce  binding  in  Jurkat 
CD44.C286A transfectant. Jur- 
kat transfectants were harvested, 
washed  extensively, and  then 
counted. Equal numbers of each 
transfectant were divided into 
two  microfuge tubes. 10  btl of 
anti-CD44  mAb  (F.10-44-2; 
Serotec) were added to each tube 
and incubated on ice for 20 rain. 
After incubation, excess antibod- 
ies  were removed by  washing 
extensively with  PBS. One  of 
the  tubes was  used to  monitor 
the amount of F10-44-2 bound 
by  adding a  fluorescein-conju- 
gated rabbit anti-mouse Ig anti- 
body. The other tube was used 
to monitor the degree of binding 
of HA by adding F-HA. All sam- 
ples were fixed and analyzed  in a 
FACScan  |  At least 5,000 cells 
were  analyzed in each sample. 
Shaded areas were negative con- 
trols, which were cells first incu- 
bated  with unconjugated HA 
and then stained  with F-HA. 
1992  Interactions between CD44 and Hyaluronic Acid tutively  bind  low  levels  F-HA,  while  binding  in Jurkat 
CD44  transfectants  require  cellular  activation.  Therefore, 
constitutive binding of low levels of F-HA and activation- 
induced  binding  of high levels  F-HA may have  different 
cellular requirements. 
In addition to the transmembrane domain, the cytoplasmic 
domain of CD44 is also important in the binding of F-HA 
(reference 19 and Liu, D., manuscript submitted for publi- 
cation).  R.ecently,  we found that induction  of binding in 
Jurkat CD44 transfectant was inhibited by cytochalasin D, an 
inhibitor ofmicrotubular function (Liu, D., manuscript sub- 
mitted for publication). Activation of human T  cells by im- 
mobilized anti-CD3 mAb has been reported to enhance the 
interactions between CD44 and cytoskeletal proteins (46). 
Activation of  Jurkat cells with anti-CD3 mAb also caused the 
reorganization of the cytoskeletal proteins (47).  These in- 
teractions may facilitate the clustering of CD44 on the cell 
surface, a condition critical for binding ofF-HA (34,  35). 
Binding of HA can be induced by a unique group ofanti- 
CD44  mAb  (18,  19).  We  confirmed  these  findings  with 
monoclonal anti-CD44  antibody, F10-44-2.  F10-44-2  in- 
duced binding in all five Jurkat wild-type CD44  transfec- 
tants and in CD44.C295A transfectants. The levels of bind- 
ing induced by anti-F44.10  were lower than the levels of 
binding induced with anti-CD3. Therefore, aggregation of 
CD44 on the cell surface may enable the cell to bind low 
levels of HA, but cellular activation is essential for binding 
of higher levels of HA.  The reason why F10-44-2  could 
not  induce  binding  in  CD44.C286A  was  not  because 
CD44.C286A  bound  less  F10-44-2  antibody.  Both  wild- 
type CD44 transfectant and CD44.C286A transfectants ex- 
press  comparable levels  of F44-10-2  epitopes  as  demon- 
strated by immunofluorescent staining and FACS  analysis. 
Therefore,  antibody-induced  binding  is  more  complex 
than  simply  binding  of antibody  to  the  cell  surface  and 
cross-linking of CD44  molecules on the  cell surface.  This 
interpretation was further supported by our recent findings 
that antibody-induced binding  was also inhibited by cyto- 
chalsin D  and requires the cytoplasmic domain ofCD44 (Liu, 
D., manuscript submitted for publication). 
The results presented in this paper provide new evidence 
that interactions between CD44H  on the  cell surface and 
soluble HA is a complex and dynamic process. More spe- 
cifically, the cysteine residue in the transmembrane domain 
is critical for the binding  of HA.  We hypothesize that in 
order for a cell to bind high levels of HA several cellular in- 
teractions must be achieved. These interactions may involve 
interactions between CD44 and CD44 or CD44 and other 
cytoplasmic or membrane proteins. In the absence of Cys286, 
one or more of these interactions may be impaired, result- 
ing in the failure of CD44 to bind high levels HA. Binding 
of F-HA to cell surface provides a quick, reproducible and 
quantitative assay for studying interactions between CD44 
and HA. However, the conformation of HA in solution may 
be different from HA in extracellular matrix. Therefore, our 
conclusions  apply only to  the  interactions  between  CD44 
and HA in solution. Moreover, in addition to HA, CD44 
also interacts with other hgands. Whether mutations that af- 
fect interactions between CD44 and HA also affect interac- 
tions between CD44 and these other ligands is not known. 
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